Triage of ASC-H: A meta-analysis of the accuracy of high-risk HPV testing and other markers to detect cervical precancer

Cancer Cytopathology

Volumn 124, Issue 4, 2016, Pages 261-272

  Xu, Lan ^a   Verdoodt, Freija ^a,b   Wentzensen, Nicolas ^c   Bergeron, Christine ^d   Arbyn, Marc ^a  

^a SCIENTIFIC INSTITUTE OF PUBLIC HEALTH   (Belgium)

^b DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^c NATIONAL CANCER INSTITUTE   (United States)

^d LABORATOIRE CERBA   (France)

Author keywords

atypical squamous cells; cannot exclude high grade squamous intraepithelial lesion (ASC H); cervical cancer; cervical intraepithelial neoplasia; diagnostic test accuracy; human papillomavirus (HPV); meta analysis; triage

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; KI 67 ANTIGEN;

ARTICLE; ASSAY; CANCER GRADING; CANCER RISK; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DNA METHYLATION; GENE; GENOTYPING TECHNIQUE; HIGH GRADE SQUAMOUS INTRAEPITHELIAL LESION; HUMAN; HUMAN PAPILLOMAVIRUS DNA TEST; HYBRID CAPTURE 2 ASSAY; META ANALYSIS; MULTIPLEX POLYMERASE CHAIN REACTION; PAX1 GENE; PRIORITY JOURNAL; PROBABILITY; SENSITIVITY AND SPECIFICITY; SQUAMOUS INTRAEPITHELIAL LESION OF THE CERVIX; STAINING; SYSTEMATIC REVIEW; UTERINE CERVIX CARCINOMA IN SITU; CANCER STAGING; EARLY CANCER DIAGNOSIS; EMERGENCY HEALTH SERVICE; FEMALE; PAPILLOMAVIRUS INFECTIONS; PATHOLOGY; PRECANCER; PROCEDURES; TUMOR INVASION; UTERINE CERVIX DYSPLASIA; UTERINE CERVIX TUMOR; VAGINA SMEAR; VIROLOGY;

ATYPICAL SQUAMOUS CELLS OF THE CERVIX; EARLY DETECTION OF CANCER; FEMALE; HUMAN PAPILLOMAVIRUS DNA TESTS; HUMANS; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PAPILLOMAVIRUS INFECTIONS; PRECANCEROUS CONDITIONS; SENSITIVITY AND SPECIFICITY; SQUAMOUS INTRAEPITHELIAL LESIONS OF THE CERVIX; TRIAGE; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 84963959933     PISSN: 1934662X     EISSN: 19346638     Source Type: Journal    
DOI: 10.1002/cncy.21661     Document Type: Article

References (60)

1. Arbyn M, Castellsague X, de Sanjose S, et al., Worldwide burden of cervical cancer in 2008. Ann Oncol. 2011; 22: 2675-2686.
2. Solomon D, Davey D, Kurman R, et al., The 2001 Bethesda system: terminology for reporting results of cervical cytology. JAMA. 2002; 287: 2114-2119.
3. Davey DD, Greenspan DL, Kurtycz DF, Husain M, Austin RM,. Atypical squamous cells, cannot exclude high-grade squamous intraepithelial lesion: review of ancillary testing modalities and implications for follow-up. J Low Genit Tract Dis. 2010; 14: 206-214.
4. Zhao C, Moriarty AT, Ghofrani M, et al., Human papillomavirus testing and reporting rates in 2012: results of a College of American Pathologists national survey. Arch Pathol Lab Med. 2015; 139: 757-761.
5. Pretorius RG, Peterson P, Novak S, et al., Comparison of two signal-amplification DNA tests for high-risk HPV as an aid to colposcopy. J Reprod Med. 2002; 47: 290-296.
6. Galliano GE, Moatamed NA, Lee S, Salami N, Apple SK,. Reflex high risk HPV testing in atypical squamous cells, cannot exclude high grade intraepithelial lesion: a large institution's experience with the significance of this often ordered test. Acta Cytol. 2011; 55: 167-172.
7. Wang ZM,. PAX1 methylation analysis by MS-HRM is useful in triage of high-grade squamous intraepithelial lesions. Asian Pac J Cancer Prev. 2014; 15: 891-894.
8. Monsonego J, Pollini G, Evrard MJ, et al., Detection of human papillomavirus genotypes among high-risk women: a comparison of Hybrid Capture and Linear Array tests. Sex Transm Dis. 2008; 35: 521-527.
9. Arbyn M, Ronco G, Anttila A, et al., Evidence regarding HPV testing in secondary prevention of cervical cancer. Vaccine. 2012; 30 (suppl 5): F88-F99.
10. Arbyn M, Roelens J, Simoens C, et al., Human papillomavirus testing versus repeat cytology for triage of minor cytological cervical lesions. Cochrane Database Syst Rev. 2013; 3: 1-201.
11. Massad LS, Einstein MH, Huh WK, et al., 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. J Low Genit Tract Dis. 2013; 17: S1-S27.
12. Arbyn M, Anttila A, Jordan J, et al., European guidelines for quality assurance in cervical cancer screening. Second edition-summary document. Ann Oncol. 2010; 21: 448-458.
13. Saslow D, Solomon D, Lawson HW, et al., American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. Am J Clin Pathol. 2012; 137: 516-542.
14. Wright TC Jr, Massad LS, Dunton CJ, et al., 2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests. Am J Obstet Gynecol. 2007; 197: 346-355.
15. Sherman ME, Castle PE, Solomon D,. Cervical cytology of atypical squamous cells-cannot exclude high-grade squamous intraepithelial lesion (ASC-H): characteristics and histologic outcomes. Cancer. 2006; 108: 298-305.
16. Katki HA, Schiffman M, Castle PE, et al., Five-year risks of CIN 3 + and cervical cancer among women who test Pap-negative but are HPV-positive. J Low Genit Tract Dis. 2013; 17: S56-S63.
17. Cohen D, Austin RM, Gilbert C, Freij R, Zhao C,. Follow-up outcomes in a large cohort of patients with human papillomavirus-negative ASC-H cervical screening test results. Am J Clin Pathol. 2012; 138: 517-523.
18. Arbyn M, Kyrgiou M, Simoens C, et al., Peri-natal mortality and other severe adverse pregnancy outcomes associated with treatment of cervical intraepithelial neoplasia: a meta-analysis. BMJ. 2008; 337: a1284.
19. Kyrgiou M, Arbyn M, Martin-Hirsch P, Paraskevaidis E,. Preterm birth after treatment for cervical precancer: an issue yet to be resolved. BMJ. 2012; 345: e5847.
20. Whiting PF, Rutjes AW, Westwood ME, et al., QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011; 155: 529-536.
21. Reitsma JB, Glas AS, Rutjes AW, et al., Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews. J Clin Epidemiol. 2005; 58: 982-990.
22. Harbord RM, Whiting P,. Metandi: meta-analysis of diagnostic accuracy using hierarchical logistic regression. Stata J. 2009; 9: 211-229.
23. Nyaga VN, Arbyn M, Aerts M,. Metaprop: a Stata command to perform meta-analysis of binomial data. Arch Public Health. 2014; 72: 39.
24. Harris R, Bradburm M, Deeks J, et al., Metan: fixed- and random-effects meta-analysis. Stata J. 2008; 8: 3-26.
25. Takwoingi Y, Deeks J,. METADAS: a SAS macro for meta-analysis of diagnostic accuracy studies. Quick reference and worked example. Version 1.3. http://dta.cochrane.org/sites/dta.cochrane.org/files/uploads/MetaDAS%20Quick%20Reference%20v1.3%20May%202012.pdf. Accessed May 20, 2012.
26. Passamonti B, Gustinuci D, Rechia P, et al., Expression of p16 in abnormal Pap-tests as an indicator of CIN2 + lesions: a possible role in the low grade ASC/US and L/Sil (lg) cytologic lesions for screening prevention of uterine cervical tumours. Pathologica. 2010; 102: 6-11.
27. Alaghehbandan R, Fontaine D, Bentley J, et al., Performance of ProEx C and PreTect HPV-proofer E6/E7 mRNA tests in comparison with the Hybrid Capture 2 HPV DNA test for triaging ASC-US and LSIL cytology. Diagn Cytopathol. 2013; 41: 767-775.
28. Katki HA, Schiffman M, Castle PE, et al., Five-year risks of CIN 3 + and cervical cancer among women with HPV-positive and HPV-negative high-grade Pap results. J Low Genit Tract Dis. 2013; 17: S50-S55.
29. Castle PE, Fetterman B, Thomas CJ, et al., The age-specific relationships of abnormal cytology and human papillomavirus DNA results to the risk of cervical precancer and cancer. Obstet Gynecol. 2010; 116: 76-84.
30. Owens CL, Moats DR, Burroughs FH, Gustafson KS,. "Low-grade squamous intraepithelial lesion, cannot exclude high-grade squamous intraepithelial lesion" is a distinct cytologic category: histologic outcomes and HPV prevalence. Am J Clin Pathol. 2007; 128: 398-403.
31. Srodon M, Parry DH, Ronnett BM,. Atypical squamous cells, cannot exclude high-grade squamous intraepithelial lesion. Cancer. 2006; 108: 32-38.
32. Liberati A, Altman DG, Tetzlaff J, et al., The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009; 6: e1000100.
33. Lonky NM, Felix JC, Naidu YM, Wolde-Tsadik G,. Triage of atypical squamous cells of undetermined significance with Hybrid Capture II: colposcopy and histologic human papillomavirus correlation. Obstet Gynecol. 2003; 101: 481-489.
34. Wentzensen N, Schwartz L, Zuna RE, et al., Performance of p16/Ki-67 immunostaining to detect cervical cancer precursors in a colposcopy referral population. Clin Cancer Res. 2012; 18: 4154-4162.
35. Lorenzato M, Caudroy S, Nou JM, et al., Contribution of DNA ploidy image cytometry to the management of ASC cervical lesions. Cancer. 2008; 114: 263-269.
36. You K, Geng L, Guo Y, Qiao J,. The use of HPV test in patients with cervical cytology interpreted as ASC-H. Acta Cytol. 2013; 57: 85.
37. Wu HH, Allen SL, Kirkpatrick JL, Elsheikh TM,. Reflex high-risk human papilloma virus DNA test is useful in the triage of women with atypical squamous cells cannot exclude high-grade squamous intraepithelial lesion. Diagn Cytopathol. 2006; 34: 707-710.
38. Reid-Nicholson M, Gatscha RM, Riedel ER, Lin O,. Atypical squamous cells, cannot exclude high grade intraepithelial lesion (ASC-H): does HPV matter? Diagn Cytopathol. 2007; 35: 1-5.
39. You K, Liang X, Qin F, Guo Y, Geng L,. High-risk human papillomavirus DNA testing and high-grade cervical intraepithelial lesions. Aust N Z J Obstet Gynaecol. 2007; 47: 141-144.
40. Bandyopadhyay S, Austin RM, Dabbs D, Zhao C,. Adjunctive human papillomavirus DNA testing is a useful option in some clinical settings for disease risk assessment and triage of females with ASC-H Papanicolaou test results. Arch Pathol Lab Med. 2008; 132: 1874-1881.
41. Rao A, Pather S, Dalrymple C, Mackie A, Deans R, Carter J,. The role of HPV testing in patients with possible high-grade cervical cytology. J Obstet Gynaecol Res. 2009; 35: 503-506.
42. Samarawardana P, Dehn DL, Singh M, et al., p16(INK4a) is superior to high-risk human papillomavirus testing in cervical cytology for the prediction of underlying high-grade dysplasia. Cancer Cytopathol. 2010; 118: 146-156.
43. Sung CO, Kim SR, Oh YL, Song SY,. The use of p16(INK4A) immunocytochemistry in "atypical squamous cells which cannot exclude HSIL" compared with "atypical squamous cells of undetermined significance" in liquid-based cervical smears. Diagn Cytopathol. 2010; 38: 168-171.
44. Gilani SM, Tashjian R, Fathallah L,. Cervical cytology with a diagnosis of atypical squamous cells, cannot exclude high-grade squamous intraepithelial lesion (ASC-H): a follow-up study with corresponding histology and significance of predicting dysplasia by human papillomavirus (HPV) DNA testing. Arch Gynecol Obstet. 2014; 289: 645-648.
45. Koo YJ, Hahn HS, Lee IH, et al., Dual immunostaining of cervical cytology specimens with atypical squamous cells for p16/Ki-67 does not exclude the existence of a high-grade squamous intraepithelial lesion. Virchows Arch. 2013; 463: 689-696.
46. Lee S, Kim JW, Hong JH, et al., Clinical significance of HPV DNA cotesting in Korean women with ASC-US or ASC-H. Diagn Cytopathol. 2014; 42: 1058-1062.
47. Killeen JL, Dye T, Grace C, Hiraoka M,. Improved abnormal Pap smear triage using cervical cancer biomarkers. J Low Genit Tract Dis. 2014; 18: 1-7.
48. Pabuccu EG, Taskin S, Ustun H, et al., Diagnostic performance of p16 staining in atypical squamous cells 'cannot exclude high-grade squamous epithelial lesion' in predicting high-grade cervical pathology. J Obstet Gynaecol. 2014; 34: 730-734.
49. Chen L, Baker S, De PG, Yang B,. HPV testing results and histologic follow-up in women with ASC-H cytology in different age groups. J Am Soc Cytopathol. 2015; 4: 225-231.
50. Monsonego J, Pollini G, Evrard MJ, et al., Linear Array genotyping and Hybrid Capture II assay in detecting human papillomavirus genotypes in women referred for colposcopy due to abnormal Papanicolaou smear. Int J STD AIDS. 2008; 19: 385-392.
51. Castle PE, Sideri M, Jeronimo J, Solomon D, Schiffman M,. Risk assessment to guide the prevention of cervical cancer. Am J Obstet Gynecol. 2007; 197: 356.e1-356.e6.
52. Saslow D, Solomon D, Lawson HW, et al., American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin. 2012; 62: 147-172.
53. Arbyn M, Verdoodt F, Snijders PJF, et al., Accuracy of human papillomavirus testing on self-collected versus clinician-collected samples: a meta-analysis. Lancet Oncol. 2014; 15: 172-183.
54. Arbyn M, Roelens J, Martin-Hirsch P, Leeson S, Wentzensen N,. Use of HC2 to triage women with borderline and mild dyskaryosis in the UK. Br J Cancer. 2011; 105: 877-880.
55. Arbyn M, Martin-Hirsch P, Wentzensen N,. Human papillomavirus-based triage of women showing a cervical cytology result of borderline or mild dyskaryosis. BJOG. 2010; 117: 641-644.
56. Katki HA, Schiffman M, Castle PE, et al., Five-year risks of CIN 3 + and cervical cancer among women with HPV testing of ASC-US Pap results. J Low Genit Tract Dis. 2013; 17: S36-S42.
57. Gupta S, Sodhani P, Chachra KL, Singh V, Sehgal A,. Outcome of "atypical squamous cells" in a cervical cytology screening program: implications for follow up in resource limited settings. Diagn Cytopathol. 2007; 35: 677-680.
58. Liman AK, Giampoli EJ, Bonfiglio TA,. Should women with atypical squamous cells, cannot exclude high-grade squamous intraepithelial lesion, receive reflex human papillomavirus-DNA testing? Cancer. 2005; 105: 457-460.
59. Arbyn M, Martin-Hirsch P, Buntinx F, et al., Triage of women with equivocal or low-grade cervical cytology results. A meta-analysis of the HPV test positivity rate. J Cell Mol Med. 2009; 13: 648-659.
60. Guyatt GH, Oxman AD, Kunz R, et al., What is "quality of evidence" and why is it important to clinicians? BMJ. 2008; 336: 995-998.